Vildagliptin ameliorates biochemical, metabolic and fatty changes associated with non alcoholic fatty liver disease

Pakistan Journal of Medical Sciences

Volumn 32, Issue 6, 2016, Pages 1396-1401

  Hussain, Mazhar ^a   Babar, Muhammad Zafar Majeed ^a   Hussain, Muhammad Shahbaz ^a   Akhtar, Lubna ^a  

^a Sheikh Zayed Medical College and Hospital   (Pakistan)

Author keywords

Body weight; Fatty liver; Grading; Lipid profile; Liver enzymes; Steatosis; Ultrasound; Vildagliptin

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL; VILDAGLIPTIN;

ABSENCE OF SIDE EFFECTS; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; BODY WEIGHT; CASE CONTROL STUDY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; DRUG TOLERABILITY; DYSLIPIDEMIA; ECHOGRAPHY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PAKISTAN; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 85007500595     PISSN: 1682024X     EISSN: None     Source Type: Journal    
DOI: 10.12669/pjms.326.11133     Document Type: Article

References (31)

1. Ashtaris S, Pourhoseingholi MA, Zali MR. Non alcoholic fatty liver disease in Asia: prevention and planning. World J Hepatol. 2015;7(13):1788-1796. doi:10.4254/wjh.v7.i13.1788
2. Milic S, Lulic D, Stimac D. Non alcoholic fatty liver disease and obesity: Biochemical, metabolic and clinical presentations. World J Gastroenterol. 2014;20(28):9330-9337. doi:10.3748/wjg.v20.i28.9330
3. Caldwell S, Argo C. The natural history of Non alcoholic fatty liver disease. Dig Dis Sci. 2010;28:162-168. doi: 10.1159/000282081
4. Fargion S, Porzio M, Fracanzani AL. Non alcoholic fatty liver disease and vascular disease: State of the art. World J Gastroenterol. 2014;20(37):1306-13324. doi:10.3748/wjg.v20. i37.13306
5. Hashimoto E, Tanjgi M, Tokusghige K. Characteristics and diagnosis of NAFLD/NASH. J Gastroenterol Hepatol. 2013;28(4):64-76. doi:10.111/jgh.12271
6. Centis E, Marzocchi R, Suppini A, Grave RD, Villanova N, Hickman IJ. The role of life style change in the prevention and treatment of NAFLD. Curr Pharm Des. 2013;19:5270-5279. doi:10.1186/1741-7015-9-70
7. Barb D, Portillo-Sanchez P, Cusi K. Pharmacological management of non alcoholic fatty liver disease. Metab Clin Exp. 2016;65:1183-1195. doi:10.16/j.metabol.2016.04.004
8. Duez H, Cariou B, Staels B. DPP-4 inhibitors in the treatment of type 2 diabetes. Biochem Pharmacol. 2012:83(7):823-832. doi:10.1016/j.bcp.2011.11.028
9. Horie A, Tokuyama Y, Ishizuka T, Suzuki Y, Marumo K, Oshikiri K. The dipeptidyl peptidase-4 inhibitor vildagliptin has the capacity to repair β-cell dysfunction and insulin resistance. Horm Metab Res. 2014;46:814-818. doi: 10.1055/ s-0034-1382015.
10. Yilmaz Y, Atug O, Yonal O, Duman D, Ozdogon O, Imeryuz N. Dipeptidyl peptidase-IV inhibitors:therapeutic potential in non alcoholic fatty liver disease. Med Sci Monit. 2009;15(4):1-5.
11. Takaki A, Kawai D, Yamamoto K. Multiple hits including oxidative stress as pathogenesis and treatment target in non alcoholic steatohepatotis(NASH). Int J Mol Sci. 2013;14:20704-20728. doi:10.3390/ijms.141020704
12. Scheen AJ., Cardiovascular effect of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes. Post Med J. 2013;125(3):7-20. doi:10.3390/ijms141020704
13. Dasarathy S, Dasarathy J, Khiyami A, Joseph R, Lopez R, Mccullough AJ. Validity of real time ultrasound in the diagnosis of hepatic steatosis: a prospective study. J Hepatol. 2009;51(6):1061-1067. doi:10.1016/j.jhep.2009.09.001
14. Promrat K, Kleiner DE, Niemeier HM, Jackvony E, Kearns M, Wands JR. Randomized controlled trial testing the effect of weight loss on non alcoholic steatohepatitis. Hepatology. 2010;51(1):121-129. doi:10.1002/hep.23276
15. Wong VW, Chan RS, Wong GL, Cheung BH, Chu WC, Yeung DK. Community based life style modification programme for non alcoholic fatty liver disease: a randomized controlled trials. J Hepatol. 2013;59(3):536-542. doi:10.1016/j.jhep.2013.04.013
16. Gomez EV, Perez YM, Berot LC, Gonzalez AT, Oramas BG, Fabian LG. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gasteroenterol. 2015;149(2):367-378. doi:10.1053/j.gastro.2015.04.005
17. Ozturk ZA, Kadayifci A. Insulin sensitizers for the treatment of non alcoholic fatty liver disease. World J Hepatol. 2014;6(4):199-206. doi:10.4254/wjh.v6.i4.199
18. Li CL, Zhao LJ, Zhou XL, Wu HX, Zhao JJ. Effect of glucagon like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors for the treatment of non alcoholic fatty liver disease. J Huazhong Univ Sci Technol Med Sci. 2015;35(3):333-336. doi:10.1007/s11596-015-1433-2
19. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epideminiology of non alcoholic fatty liver disease- meta-analytic assessment of prevalence, incidence and outcomes. Hepatolgy. 2016;64(1):73-84. doi:10.1002/hep.28431
20. Qin X, Shen H, Liu M, Yang Q, Zheng S, Sabo M, et al. GLP-1 reduces intestinal lymph flow, triglycerides absorption and apolipoprotein production in rats. Am J Physiol Gastrointest Liver Physiol. 2005;288:943-949. doi:10.1152/ ajpqi.00303.2004
21. Aller R, Izaola O, Gomez S, Tafur C, Gonzalez G, Berroa E. Effect of silymarin plus vitamin E in patients with non alcoholic fatty liver disease. A randomized clinical pilot study. Eur Rev Med Pharmacol Sci. 2015;19:3118-3124.
22. Rizzo MR, Marfella R, Barbieri M, Paolisso G. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes. Diabetes Care. 2012;35:2076-2082. doi:10.2337/dc12-0199
23. Macauley M, Hollingsworth KG, Smith FE, Thelwall PE, Mrabeh AA, Schweizer A. Effect of vildagliptin on hepatic steatosis. J Clin Endocrinol Metab. 2015;100(4):1578-1585. doi:10.1210/jc.2014-3794
24. Mookkan J, De S, Shetty P, Kulkarni NM, Devisingh V, Jaji MS. Combination of vildagliptin and rosiglitazone ameliorates non alcoholic fatty liver disease in C57BL/6 mice. Indian J Pharmacol. 2014;46(1):46-50. doi: 10.4103/0253-7613.125166
25. Shirakawa J, Fujii H, Ohnuma K, Sato K, Ito Y, Kaji M. Diet induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice. Diabetes. 2011; 60(4):1246-1257. doi:10.2337/db10-1338
26. Yilmaz Y, Yonal O, Deyneli O, Celikel CA, Kalayci C, Duman DG. Effect of sitagliptin in diabetic patients with non alcoholic steatohepatitis. Acta Gastroenterol Belg. 2012;75(2):240-244.
27. Sanyal AJ, Mofrad PS, Contos MJ, Sargeant C, Luketic VA, Sterling RK. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of non alcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2004;2(12):1107-1115. doi:10.1016/s1542-3565(04)00457-4
28. Chalasani NP, Sanyal AJ, Kowdley KV, Robuck PR, Hoofnagle J, Kleiner DE. Pioglitazone versus vitamin E versus placebo for the treatment of non diabetic patients with non alcoholic steatohepatitis: pivens trials design. Contemp Clin Trials. 2009;31(1):86-96. doi:10.1016/j.cct.2008.09.003
29. Hernaez R, Lazo M, Bonekamp S, Kamel I, Brancati FL, Guallar E. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a metaanalysis. Hepatology. 2011;54:1082-1090. doi:10.1002/ hep.24452
30. Junker AE, Gluud L, Holst JJ, Knop FK, Vilsholl T. Diabetic and non diabetic patients with non alcoholic fatty liver disease have impaired incretin effect and fasting hyperglucagonaemia. J Intern Med. 2016;279:485-493. doi:10.111/joim.12462
31. Firneisz G, Varga T, Lengyel G, Feher J, Ghyczy D, Wichmann B. Serum dipeptidyl peptidase-4 activity in insulin resistant patient of NAFLD: a novel liver disease biomarkers. PLoS ONE. 2010;5(8):12226. doi:10.1371/journal.pone.0012226